People with familial hypercholesterolaemia (FH, inherited high cholesterol) are at high risk for atherosclerotic cardiovascular disease, especially if untreated or initiation of lipid-lowering therapy is delayed. But the level of risk is not the same in all individuals. A key question for clinicians is how to identify those who would clearly benefit from treatment with a PCSK9 inhibitor.

Professor Raul Santos(Hospital Israelita Albert Einstein and University of São Paulo, Brazil) discusses results from a cohort study proposing coronary artery calcium score as a risk tool. Read the report » Watch the video »

In the latest Editors’ Corner, Professor Gerald Watts (University of Western Australia, Perth, Australia) and Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) weigh up the evidence – and the outstanding questions. Read the report »